Valion Bio grants 45,000 stock options to counsel

Valion Bio, Inc. granted its General Counsel & SVP of Legal, Melinda Lackey, an employee stock option to purchase 45,000 shares of common stock at an exercise price of $0.96 per share.

Rhea-AI Filing Summary

Valion Bio, Inc. granted its General Counsel & SVP of Legal, Melinda Lackey, an employee stock option to purchase 45,000 shares of common stock at an exercise price of $0.96 per share.

The option vests 25% on the first anniversary of the grant date, with the remaining 75% vesting in twelve equal quarterly installments over the following three years, and expires on May 1, 2036. After this grant, she holds options for 45,000 shares directly. This is a compensation-related award rather than an open-market purchase.

Insider Trade Summary

Grant/Award: 45,000 shares

Grant/Award 1 txn

Insider Lackey Melinda

Role General Counsel & SVP of Legal

Type	Security	Shares	Price	Value
Grant/Award	Employee Stock Option (Right to Purchase)	45,000	$0.00	$0.00

Holdings After Transaction: Employee Stock Option (Right to Purchase) — 45,000 contracts (Direct)

Footnotes (1)

1. F1. The stock option vests as follows: (i) 25% upon the first anniversary of the grant date, and (ii) the remaining 75% in a series of twelve (12) successive equal quarterly installments, rounded downward to the nearest whole share, measured from the first anniversary of the grant date, such that 100% of the stock option will be vested upon the fourth anniversary of the grant date.

Key Figures

Option grant size: 45,000 shares Exercise price: $0.96 per share Expiration date: May 1, 2036 +3 more

6 metrics

Option grant size 45,000 shares Employee stock option underlying common stock

Exercise price $0.96 per share Strike price for employee stock option

Expiration date May 1, 2036 Option term end date

Post-transaction derivative holdings 45,000 options Total options held after grant

Initial vesting tranche 25% of options Vests on first anniversary of grant date

Remaining vesting schedule 75% over 12 quarters Equal quarterly installments after first anniversary through year four

Key Terms

Employee Stock Option (Right to Purchase), vesting, exercise price, expiration date, +1 more

5 terms

Employee Stock Option (Right to Purchase) financial

"security_title: Employee Stock Option (Right to Purchase)"

vesting financial

"The stock option vests as follows: (i) 25% upon the first anniversary"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"conversion_or_exercise_price: 0.9600"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-05-01T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Valion Bio (VBIO) disclose in this Form 4 filing?

Valion Bio reported a stock option grant to its General Counsel, Melinda Lackey, covering 45,000 shares of common stock at a $0.96 exercise price. The award is compensation-related and vests over four years, with an expiration date in 2036.

How many Valion Bio (VBIO) shares are covered by Melinda Lackey’s new options?

The new employee stock option grants Melinda Lackey the right to purchase 45,000 shares of Valion Bio common stock. All 45,000 underlying shares are tied to this single option award and represent her total derivative holdings after the reported transaction.

What is the exercise price and term of the new Valion Bio (VBIO) stock options?

The employee stock option has a $0.96 per share exercise price and expires on May 1, 2036. This gives the executive a long-dated right to buy Valion Bio common stock at that fixed price if the option becomes vested.

How do Melinda Lackey’s Valion Bio (VBIO) options vest over time?

The option vests 25% on the first anniversary of the grant date, then the remaining 75% vests in twelve equal quarterly installments. This quarterly vesting begins one year after the grant and continues so that the option is fully vested by its fourth anniversary.

Is this Valion Bio (VBIO) Form 4 transaction an open-market purchase or a grant?

The reported transaction is a grant of employee stock options, coded as a grant or award acquisition, not an open-market share purchase. The company awarded 45,000 options as compensation, with vesting conditions and a $0.96 exercise price, rather than buying shares on the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/04/2026 - 04:08 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lackey Melinda

(Last) (First) (Middle)

1305 E. HOUSTON STREET

BLG. 1, STE. 311

(Street)

SAN ANTONIO TEXAS 78205

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Valion Bio, Inc. [ VBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	General Counsel & SVP of Legal

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Purchase)	$0.96	05/01/2026		A		45,000		(1)	05/01/2036	Common Stock	45,000	$0	45,000	D

Explanation of Responses:

1. The stock option vests as follows: (i) 25% upon the first anniversary of the grant date, and (ii) the remaining 75% in a series of twelve (12) successive equal quarterly installments, rounded downward to the nearest whole share, measured from the first anniversary of the grant date, such that 100% of the stock option will be vested upon the fourth anniversary of the grant date.

	/s/ Melinda Lackey	05/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)